Evaluation of QTc and Tp-e changes in rheumatoid arthritis and ankylosing spondylitis patients treated with biological drugs
-
Published:2023-12-01
Issue:2
Volume:5
Page:39-47
-
ISSN:2820-817X
-
Container-title:Plant Biotechnology Persa
-
language:en
-
Short-container-title:pbp
Author:
Aghdashi Mir AmirORCID, Hajahmadi pourrafsanjan MojganORCID, Mokari TyyebeORCID
Publisher
Apex Publishing
Reference38 articles.
1. Jang DI, Lee AH, Shin HY, Song HR, Park JH, Kang TB, Lee SR, Yang SH. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. International journal of molecular sciences. 2021 Mar 8;22(5):2719. 2. van Loo G, Bertrand MJ. Death by TNF: a road to inflammation. Nature Reviews Immunology. 2023 May;23(5):289-303. 3. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure.N Engl J Med. 1990; 323:236–241. 4. Andretto V, Dusi S, Zilio S, Repellin M, Kryza D, Ugel S, Lollo G. Tackling TNF-α in autoinflammatory disorders and autoimmune diseases: from conventional to cutting edge in biologics and RNA-based nanomedicines. Advanced Drug Delivery Reviews. 2023 Sep 1:115080. 5. Cantini F, Niccoli L, Nannini C, Cassara E, Kaloudi O, Favalli EG, Becciolini A, Biggioggero M, Benucci M, Gobbi FL, Grossi V. Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. InSeminars in Arthritis and Rheumatism 2016 Apr 1 (Vol. 45, No. 5, pp. 519-532). WB Saunders.
|
|